Current Filters

Showing 1 - 10 results of 4339

Dolutegravir / abacavir / lamivudine (Triumeq) (Last Updated: Jul 31, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Triumeq
Manufacturer:
ViiV Healthcare
Submission Type:
Initial
Indications:

HIV Infection

Pirfenidone (Esbriet) (Last Updated: Aug 29, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Esbriet
Manufacturer:
Hoffmann-La Roche Ltd.
Submission Type:
Resubmission
Indications:

Pulmonary fibrosis (idiopathic, mild to moderate)

Certolizumab pegol (Cimzia) (Last Updated: Sep 7, 2018)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Cimzia
Manufacturer:
UCB Canada Inc.
Submission Type:
Initial
Indications:

Arthritis, psoriatic

Taliglucerase alfa (Elelyso) (Last Updated: Aug 15, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Elelyso
Manufacturer:
Pfizer Canada Inc.
Submission Type:
Initial
Indications:

Gaucher disease

Eslicarbazepine acetate (Aptiom) (Last Updated: Aug 15, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Aptiom
Manufacturer:
Sunovion Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Epilepsy, partial-onset seizures

Ledipasvir / Sofosbuvir (Harvoni) (Last Updated: Sep 15, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Harvoni
Manufacturer:
Gilead Sciences Canada Inc.
Submission Type:
Initial
Indications:

Hepatitis C, chronic

Elosulfase alfa (Vimizim) (Last Updated: Aug 5, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Vimizim
Manufacturer:
BioMarin Pharmaceutical (Canada) Inc.
Submission Type:
Initial
Indications:

Mucopolysaccharidosis IVA (Morquio A syndrome)

Lomitapide (Juxtapid) (Last Updated: Jul 8, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Juxtapid
Manufacturer:
Aegerion Pharmaceuticals (Canada) Ltd.
Submission Type:
Initial
Indications:

Hypercholesterolemia, Homozygous Familial

Rifaximin (Zaxine) (Last Updated: Aug 5, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Zaxine
Manufacturer:
Salix Pharmaceuticals Inc.
Submission Type:
Initial
Indications:

Encephalopathy, Hepatic

Certolizumab pegol (Cimzia) (Last Updated: Jun 23, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Cimzia
Manufacturer:
UCB Canada Inc.
Submission Type:
Initial
Indications:

Ankylosing spondylitis

Download results as CSV